Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy (OPTIMAL)
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
調査の概要
状態
詳細な説明
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
California
-
Beverly Hills、California、アメリカ、90210
- California Liver Institute
-
Calabasas、California、アメリカ、91302
- Samuel Burstein, MD
-
Santa Monica、California、アメリカ、90404
- William Katkov, MD
-
Torrance、California、アメリカ、90277
- Sutha Sachar, MD
-
Torrance、California、アメリカ、90509
- Harbor UCLA Medical Professional Group
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80909
- Associates in Gastroenterology
-
Englewood、Colorado、アメリカ、80113
- South Denver Gastroenterology
-
-
Florida
-
Clearwater、Florida、アメリカ、33756
- Bay Area Gastroenterology
-
Hialeah、Florida、アメリカ、33016
- Digestive Medicine Associates
-
Lakeland、Florida、アメリカ、33805
- James Johnson, MD
-
Largo、Florida、アメリカ、33777
- Florida Center for Gastroenterology
-
North Miami Beach、Florida、アメリカ、33169
- Marwan Iskandarani, MD
-
Pinellas Park、Florida、アメリカ、33781
- Advanced Gastro and Liver Disease
-
Sarasota、Florida、アメリカ、34239
- Lee S. Mitchel, MD
-
Tampa、Florida、アメリカ、33606
- Tampa General Hospital
-
-
Illinois
-
Bourbonnais、Illinois、アメリカ、60914
- Digestive Disease Consultants
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University
-
Munster、Indiana、アメリカ、46321
- Consultants in Gastroenerology
-
Munster、Indiana、アメリカ、46321
- Consultants in Gastroenterology
-
Terre Haute、Indiana、アメリカ、47802
- Wabash Valley Infectious Disease
-
-
Iowa
-
Iowa City、Iowa、アメリカ、53342
- University of Iowa Health Center
-
-
Louisiana
-
Metairie、Louisiana、アメリカ、70006
- Metropolitan Gastroenterology Associates
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Health System
-
Farmington Hills、Michigan、アメリカ、48336
- South Oakland Gastroenterology
-
Madison Heights、Michigan、アメリカ、48071
- Union Lake Clinic
-
St Clair Shores、Michigan、アメリカ、48081
- GI Medicine Associates
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Hospital
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Health Center
-
Kansas City、Missouri、アメリカ、64132
- Michael Fedotin, MD
-
St. Louis、Missouri、アメリカ、63110
- St. Louis University Liver Center
-
St. Louis、Missouri、アメリカ、63141
- Mercy Digestive Disease
-
-
New York
-
Bronx、New York、アメリカ、10461
- NY Associates in Gastroenterology
-
Great Neck、New York、アメリカ、11203
- North Shore Gastroenterology Associates
-
Manhasset、New York、アメリカ、11030
- North Shore University Hospital
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19140
- Temple University
-
Philadelphia、Pennsylvania、アメリカ、19134
- Temple Physicians
-
Pottsville、Pennsylvania、アメリカ、17901
- Dr. Glenn S. Freed, DO
-
Wynnewood、Pennsylvania、アメリカ、19096
- Main Line Gastroenterology
-
-
Texas
-
Live Oak、Texas、アメリカ、78233
- Gastroenterology Consultants
-
San Antonio、Texas、アメリカ、78234
- Brooke Army Medical Center
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- Metropolitan Research
-
Lynchburg、Virginia、アメリカ、24501
- Medical Associates of Central Virginia
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Chronic Hepatitis C (HCV) genotype 1
- Detectable HCV-RNA within 180 days of screening
- Age ≥ 18 years
- Weight > 40 kg
- Patient and partner(s) must agree to use acceptable methods of contraception
- Written informed consent
Exclusion Criteria:
- Known co-infection with HIV or HBV
- Previous interferon or ribavirin regimen requiring discontinuation for an adverse event considered related to ribavirin and/or interferon
- Currently taking or planning on taking any prohibited medications
- Evidence of decompensated liver disease including the presence of clinical ascites, bleeding varices, or hepatic encephalopathy
- Diabetes and/or hypertension with clinically significant ocular examination findings
- Pre-existing psychiatric condition(s)
- History of severe and uncontrolled psychiatric disorders
- Active alcohol or drug abuse (not including marijuana)
- Pre-existing medical condition that could interfere with the patient's participation in the study
- Chronic obstructive pulmonary disease
- Abnormal lab values
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
他の:Group A - HCEE
Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor.
HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
|
Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
他の名前:
|
他の:Group B - Community Sites
Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
|
Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Treatment Duration Compliance Rate
時間枠:End of treatment up to treatment week 48
|
The primary objective will be to define treatment duration compliance rate (calculated as the actual treatment duration in weeks divided by the expected duration in weeks) based on individual patient treatment goals as defined in the OPTIMAL protocol for HCV patients treated with boceprevir, peginterferon and ribavirin for up to 48 weeks.
Rates will be reported for HCEEs (Group A) and community sites enrolled in the Program (Group B).
|
End of treatment up to treatment week 48
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Drug Exposure
時間枠:End of treatment up to treatment week 48
|
Total number of patients receiving treatment over specified time intervals.
|
End of treatment up to treatment week 48
|
Determination of the Rate of Sustained Viral Response (SVR) for HCV Patients Treated With Boceprevir, Peginterferon and Ribavirin at Community Sites and at HCEEs.
時間枠:Follow-up week 24
|
Rate of SVR was defined as the percentage of participants with HCV-RNA undetectable at follow-up Week 24.
All percentages were based on the total number of participants originally randomized/enrolled to that particular arm.
|
Follow-up week 24
|
Short Form Health Survey Measuring Quality of Life Reported at Baseline, End of Treatment, and Follow-up Week 24 (36 Multiple Choice Questions)
時間枠:Baseline, end of treatment, follow-up week 24
|
Determination of the quality of life for HCV patients treated with boceprevir, peginterferon and ribavirin at community sites and at HCEEs. Patient scores per subscale (8) were obtained by subtracting the lowest possible raw score from the actual raw score x 100, divided by the lowest possible raw score subtracted from the highest possible raw score. Subscale scores were averaged (with standard deviation) for Group A and Group B. Composite Scores are standardized to the general US population having a mean of 50 and a standard deviation of 10. Higher score = improved quality of life. |
Baseline, end of treatment, follow-up week 24
|
Number of Participants With Adverse Events
時間枠:Throughout entire study, at end of treatment and follow up week 24
|
Description of the adverse events and rate of events of boceprevir, peginterferon and ribavirin in HCV patients treated at community sites and at HCEEs
|
Throughout entire study, at end of treatment and follow up week 24
|
協力者と研究者
捜査官
- 主任研究者:Fred Poordad, MD、Chronic Liver Disease Foundation
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CLDF-MER-001-00
- 20111013 (その他の識別子:Western Institutional Review Board)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
慢性C型肝炎の臨床試験
-
Dokuz Eylul UniversityEge University完了MMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/C七面鳥
-
Tripep ABInovio Pharmaceuticalsわからない
-
Hadassah Medical OrganizationXTL Biopharmaceuticals引きこもった
-
Beni-Suef University完了
-
Humanity and Health Research CentreBeijing 302 Hospital完了
-
Trek Therapeutics, PBC完了慢性C型肝炎 | C型肝炎遺伝子型1 | C型肝炎(HCV) | C型肝炎ウイルス感染症アメリカ, ニュージーランド
-
Trek Therapeutics, PBC完了慢性C型肝炎 | C型肝炎(HCV) | C型肝炎遺伝子型4 | C型肝炎ウイルス感染症アメリカ
-
Meir Medical Center完了デジタルステレオ光ディスク画像からC/D比を測定する新しい技術を開発 | C/D 測定の観察者内再現性 | C/D 測定値の観測者間のばらつき
Patient education and management skills trainingの臨床試験
-
Queens College, The City University of New York完了